Search - tctmd.com

Displaying 361 - 380 of 1366

Sort: Relevancy | Date

INTEGRITTY Aims to Shine a Light on Research Bias, Including in LM Disease

News Daily News

INTEGRITTY Aims to Shine a Light on Research Bias, Including in LM Disease

Michael O'Riordan

July 12, 2022

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

News Daily News

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Michael O'Riordan

July 11, 2022

hs-Troponins and the Chest Pain Guidelines: Experts Call for Clarification

News Daily News

hs-Troponins and the Chest Pain Guidelines: Experts Call for Clarification

Yael L. Maxwell

July 08, 2022

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

News Features

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

July 07, 2022

Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines

News Daily News

Few Adults Eligible for Primary Prevention With Statins in Latest ESC Guidelines

Michael O'Riordan

July 06, 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

June 21, 2022

‘Less Is More’ for Patients With AF and Stable CAD: AFIRE Analysis

News

‘Less Is More’ for Patients With AF and Stable CAD: AFIRE Analysis

June 17, 2022

Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight

News Features

Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight

Yael L. Maxwell

June 16, 2022

COVID-19 Vaccination Tied to Better Outcomes in HF Patients

News Daily News

COVID-19 Vaccination Tied to Better Outcomes in HF Patients

June 09, 2022

TCTMD’s Top 10 Most Popular Stories for May 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2022

June 01, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

News Conference News ESC Heart Failure 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

May 26, 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

May 25, 2022

Impact of Lower BP Cutoffs to Define Hypertension Varies Globally

News Daily News

Impact of Lower BP Cutoffs to Define Hypertension Varies Globally

May 24, 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.